C.R. Bard
This article was originally published in The Gray Sheet
Executive Summary
Firm expects to receive ambulatory payment classification (APC) code for reimbursement of its EndoCinch endoscopic suturing system, indicated for treatment of gastroesophageal reflux disease (GERD), in July or October of this year, company reports during an April 17 quarterly earnings call. The APC code was originally filed in May 2000. Separately, the firm's Memotherm endoscopic biliary stent system gains FDA market go-ahead for treatment of malignant biliary obstructions. The condition affects roughly 30,000 people in the U.S. Bard's first quarter sales were up 6% to $284.8 mil. and net income advanced 5.4% to $33.2 mil